Lebanon-based Provention Bio Inc. a clinical-stage biopharmaceutical company, announced it has appointed new members to its executive management team. Lebanon-based Provention Bio Inc. a ...

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...

Provention Bio, a biopharmaceutical company based in Red Bank, recently announced the closing of a $35 million equity investment from Bridgewater-based Sanofi US. The deal is part of a previously ...

Provention Bio Inc (NASDAQ:PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ:SNY) announced plans to acquire the biopharmaceutical company. What Happened: Sanofi and Provention Bio entered ...

-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

Sanofi proposed to acquire Provention Bio for $2.9 billion in cash at a 273% premium over the previous closing price (before the deal announcement). The acquisition is expected to be a net positive ...

Type 1 diabetes, in which the immune system attacks insulin-producing beta cells of the pancreas, is caused by both genetic susceptibility and environmental factors, researchers believe. Biotech ...

Things can change quickly in the volatile biotech industry. Just ask Provention Bio (NASDAQ: PRVB). The autoimmune disease-focused drugmaker seemed on the verge of earning a major regulatory approval ...

Provention Bio Inc (NASDAQ:PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch ...

Provention Bio's leading candidate and exciting pipeline show real potential. But the biotech could face clinical, regulatory, and funding problems. The headwinds related to teplizumab have played a ...